CA2524265A1 - Procede de detection electrochimique de mutations de cellules somatiques - Google Patents

Procede de detection electrochimique de mutations de cellules somatiques Download PDF

Info

Publication number: CA2524265A1
Authority: CA; Canada
Prior art keywords: nucleic acid; polynucleotide; probe; target; target polynucleotide
Prior art date: 2003-05-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002524265A

Other languages

English (en)

Inventor

Donald M. Crothers

R. Erik Holmlin

Chunnian Shi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GeneOhm Sciences Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-02

Filing date

2004-04-30

Publication date

2004-11-18

2003-05-02 Priority claimed from US10/429,293 external-priority patent/US20040086895A1/en

2004-04-30 Application filed by Individual filed Critical Individual

2004-11-18 Publication of CA2524265A1 publication Critical patent/CA2524265A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 110
230000035772 mutation Effects 0.000 title abstract description 23
210000001082 somatic cell Anatomy 0.000 title abstract description 15
238000000835 electrochemical detection Methods 0.000 title description 2
102000039446 nucleic acids Human genes 0.000 claims abstract description 98
108020004707 nucleic acids Proteins 0.000 claims abstract description 98
150000007523 nucleic acids Chemical class 0.000 claims abstract description 98
238000001514 detection method Methods 0.000 claims abstract description 30
239000000523 sample Substances 0.000 claims description 97
108091033319 polynucleotide Proteins 0.000 claims description 60
102000040430 polynucleotide Human genes 0.000 claims description 60
239000002157 polynucleotide Substances 0.000 claims description 60
230000003321 amplification Effects 0.000 claims description 30
238000003199 nucleic acid amplification method Methods 0.000 claims description 30
230000000295 complement effect Effects 0.000 claims description 20
238000002844 melting Methods 0.000 claims description 11
230000008018 melting Effects 0.000 claims description 11
239000012491 analyte Substances 0.000 claims description 9
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 8
238000005096 rolling process Methods 0.000 claims description 8
230000000694 effects Effects 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
150000003304 ruthenium compounds Chemical class 0.000 claims 2
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
238000003869 coulometry Methods 0.000 claims 1
230000001419 dependent effect Effects 0.000 claims 1
NHWGPUVJQFTOQX-UHFFFAOYSA-N ethyl-[2-[2-[ethyl(dimethyl)azaniumyl]ethyl-methylamino]ethyl]-dimethylazanium Chemical compound CC[N+](C)(C)CCN(C)CC[N+](C)(C)CC NHWGPUVJQFTOQX-UHFFFAOYSA-N 0.000 claims 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
229910052707 ruthenium Inorganic materials 0.000 claims 1
238000009396 hybridization Methods 0.000 abstract description 39
238000003556 assay Methods 0.000 abstract description 25
108091034117 Oligonucleotide Proteins 0.000 abstract description 24
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 14
206010028980 Neoplasm Diseases 0.000 abstract description 11
239000012472 biological sample Substances 0.000 abstract description 11
201000011510 cancer Diseases 0.000 abstract description 4
108020004414 DNA Proteins 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
239000007788 liquid Substances 0.000 description 15
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 11
206010009944 Colon cancer Diseases 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
208000001333 Colorectal Neoplasms Diseases 0.000 description 8
239000002773 nucleotide Substances 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 6
108091093037 Peptide nucleic acid Proteins 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
150000002500 ions Chemical class 0.000 description 6
238000005192 partition Methods 0.000 description 6
238000006116 polymerization reaction Methods 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
108010090804 Streptavidin Proteins 0.000 description 5
238000007847 digital PCR Methods 0.000 description 5
239000000155 melt Substances 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000007363 ring formation reaction Methods 0.000 description 5
239000000243 solution Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
239000011324 bead Substances 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
108090001008 Avidin Proteins 0.000 description 3
108020004711 Nucleic Acid Probes Proteins 0.000 description 3
239000012327 Ruthenium complex Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
238000007812 electrochemical assay Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
239000010931 gold Substances 0.000 description 3
229910052737 gold Inorganic materials 0.000 description 3
239000002853 nucleic acid probe Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000012216 screening Methods 0.000 description 3
241000894007 species Species 0.000 description 3
229910052723 transition metal Inorganic materials 0.000 description 3
150000003624 transition metals Chemical class 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
238000005052 Osteryoung square wave voltammetry Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229910001882 dioxygen Inorganic materials 0.000 description 2
238000002848 electrochemical method Methods 0.000 description 2
238000003487 electrochemical reaction Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000003471 mutagenic agent Substances 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
108020004465 16S ribosomal RNA Proteins 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
108700001666 APC Genes Proteins 0.000 description 1
108091093088 Amplicon Proteins 0.000 description 1
0 C*1C*CC1 Chemical compound C*1C*CC1 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108091027874 Group I catalytic intron Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000233872 Pneumocystis carinii Species 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004082 amperometric method Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
229940098164 augmentin Drugs 0.000 description 1
238000005452 bending Methods 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
108091006374 cAMP receptor proteins Proteins 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000005591 charge neutralization Effects 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000004020 conductor Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000009223 counseling Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
-1 for example Chemical class 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000003446 ligand Substances 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
108010087904 neutravidin Proteins 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000013610 patient sample Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000002096 quantum dot Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
230000027756 respiratory electron transport chain Effects 0.000 description 1
150000003303 ruthenium Chemical class 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000010850 salt effect Methods 0.000 description 1
230000034655 secondary growth Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000014639 sexual reproduction Effects 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

CA002524265A 2003-05-02 2004-04-30 Procede de detection electrochimique de mutations de cellules somatiques Abandoned CA2524265A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/429,293 US20040086895A1 (en)	2002-11-06	2003-05-02	Method of electrochemical detection of somatic cell mutations
US10/429,293		2003-05-02
PCT/US2004/013222 WO2004099755A2 (fr)	2002-11-06	2004-04-30	Procede de detection electrochimique de mutations de cellules somatiques

Publications (1)

Publication Number	Publication Date
CA2524265A1 true CA2524265A1 (fr)	2004-11-18

Family

ID=35529856

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002524265A Abandoned CA2524265A1 (fr)	2003-05-02	2004-04-30	Procede de detection electrochimique de mutations de cellules somatiques

Country Status (2)

Country	Link
EP (1)	EP1620575A4 (fr)
CA (1)	CA2524265A1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7582421B2 (en) *	1993-11-01	2009-09-01	Nanogen, Inc.	Methods for determination of single nucleic acid polymorphisms using a bioelectronic microchip
WO1999053102A1 (fr) *	1998-04-16	1999-10-21	Packard Bioscience Company	Analyse de sequence de polynucleotides
EP1373574A4 (fr) *	2001-03-30	2007-01-03	Ge Healthcare Bio Sciences Ab	Analyse par biopuces de polymorphismes simple nucl otide

2004
- 2004-04-30 CA CA002524265A patent/CA2524265A1/fr not_active Abandoned
- 2004-04-30 EP EP04760623A patent/EP1620575A4/fr not_active Withdrawn

Also Published As

Publication number	Publication date
EP1620575A4 (fr)	2007-02-07
EP1620575A2 (fr)	2006-02-01

Publication	Publication Date	Title
US10538759B2 (en)	2020-01-21	Compounds and method for representational selection of nucleic acids from complex mixtures using hybridization
KR100557329B1 (ko)	2006-03-03	혼성화 부위 조절 올리고뉴클레오타이드 및 그의 용도
US6750020B2 (en)	2004-06-15	Method for alteration detection
EP2329039B1 (fr)	2016-05-11	Stratégies de détection et procédés destinés à la détection d'acides nucléiques au moyen de biocapteurs
US20070092880A1 (en)	2007-04-26	Invasive cleavage reaction with electrochemical readout
US20090075275A1 (en)	2009-03-19	Nucleic acid probe-immobilized substrate and method of detecting the presence of target nucleic acid by using the same
JP3752466B2 (ja)	2006-03-08	遺伝子検査方法
US20040086895A1 (en)	2004-05-06	Method of electrochemical detection of somatic cell mutations
US20040110179A1 (en)	2004-06-10	Method for alteration detection
EP1368496B1 (fr)	2010-09-22	Méthode de détection d'une alteration d'un acide nucléique
US20020182606A1 (en)	2002-12-05	Detection of single nucleotide polymorphisms
CA2524265A1 (fr)	2004-11-18	Procede de detection electrochimique de mutations de cellules somatiques
JPWO2005001091A1 (ja)	2006-08-10	核酸の変異及び多型の検出用プローブセット、それを固相化したｄｎａアレイ、並びにそれらを用いた変異及び多型の検出方法
JP3917640B2 (ja)	2007-05-23	核酸プローブ固定化基体を用いた標的核酸の存在を検出する方法
JP2024035110A (ja)	2024-03-13	変異核酸の正確な並行定量するための高感度方法
Brickell	1996	DNA probes in human diseases
JPWO2001016310A1 (ja)	2003-03-25	遺伝子変異の高感度検出方法
JP2004041109A (ja)	2004-02-12	核酸検出方法およびそれに使用されるプライマー
AU2002255762A1 (en)	2002-10-03	Method for alteration detection
JP2007282570A (ja)	2007-11-01	蛍光インターカレーターによるＳＮＰｓ検出

Legal Events

Date	Code	Title	Description
2009-04-17	EEER	Examination request
2015-05-06	FZDE	Dead	Effective date: 20150311